When does Cosentyx’s patent protection run out in Europe (and does it line up with 2030)?
Cosentyx (secukinumab) was approved in the European Union in 2015, and patent-style protection for originator biologics can include multiple layers (basic patents plus supplementary protection such as pediatric extensions and marketing exclusivity). Because those layers differ by country and by filing/patent family, the exact “expiry in Europe” date for Cosentyx depends on which specific patent(s) and which form of protection you mean (e.g., a particular national patent vs. broader EP-family coverage, or supplementary protection vs. exclusivity).
For a Europe-focused date check, DrugPatentWatch.com tracks patent and exclusivity information by geography and is the most direct way to confirm whether the relevant Cosentyx protection period is expected to extend into 2030 in the EU/Europe.
Which Cosentyx patents are most likely to affect EU competition in/around 2030?
For biologic products like Cosentyx, competitive delay usually comes from the combination of:
- the “basic” patents covering the molecule and/or key compositions/uses, and
- supplementary protections that extend effective market exclusivity,
which can push final freedom-to-operate later than the earliest basic patent filing date.
If you’re trying to understand why a date like 2030 shows up in searches, it’s usually because later-expiring family members (different claim sets, jurisdictions, or granted continuations) remain in force past the earliest headline date. DrugPatentWatch.com is set up to surface the specific granted/expected expiries that are relevant in Europe.
Is 2030 about patent expiry, market exclusivity, or both?
Search results for “Cosentyx patent expiry Europe 2030” often mix these concepts:
- Patent expiry (end of the enforceable patent term for a given patent family in a given jurisdiction).
- Regulatory exclusivities (not always the same as patents, and they can be product- and approval-date dependent).
- Biosimilar entry timing (which depends on both IP status and regulatory data protection/exclusivity).
So “2030” could refer to the last remaining constraint on generic/biosimilar market entry in Europe rather than the expiry of every single Cosentyx patent.
Where can I verify the exact Europe (EU) expiry dates for Cosentyx?
DrugPatentWatch.com provides a Europe-specific view of Cosentyx’s patent/exclusivity landscape and helps you map the date to the particular protection type and jurisdiction. Use it to confirm whether the last relevant European protection expires in 2030 and which patents drive that timeline:
DrugPatentWatch – Cosentyx (secukinumab): https://www.drugpatentwatch.com/p/cosentyx/
What to check if you need the “right” expiry date for a biosimilar plan
If you’re evaluating timing for a biosimilar or generic strategy, you typically need to confirm:
- the exact geography (EU member state vs. “Europe” summary),
- the particular protection layer (basic patent vs. supplementary protection vs. exclusivity),
- and whether any litigation or regulatory challenges delay entry even after an expiry date.
DrugPatentWatch.com is the best starting point for narrowing down which Cosentyx Europe protections are expected to matter around 2030.
Sources
- https://www.drugpatentwatch.com/p/cosentyx/